Accelerated Early Phase Decision-Making – Insider Insights to Speed Development

Access insider insights from combined perspectives of clinical pharmacology, global regulatory considerations, and private equity investors on accelerating early development timelines to go/no go decisions and early proof of concept, without shortcuts. Parexel’s early phase team and EQT LifeSciences share best practices for combining sequential early phase studies into a single protocol.

Return to Insights Center

Related Insights

Related Insights

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Playbook

Early-phase development strategies for navigating regulatory complexity in the EU

Apr 29, 2024

Blog

Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development

Jan 22, 2025

Blog

Overcoming risks in Phase 3 trials to accelerate time to market

Jan 22, 2025

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Blog

Focusing on value drivers to reduce risk in early-stage drug development

Jan 6, 2025

Show more